Gilead Sciences (GILD)

• Market cap: $133B
• 1 day: 2.24%
• 5 days: 0.41%
• 1 month: -4.92%
• 3 months: 9.89%
• 6 months: 20.67%
• Year to date: 15.96%
• 1 year: 63.40%
• 5 years: 26.83%
• 10 years: 6.00%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Employees: 17,600

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 276 | Existing positions closed: 92

56% more funds holding in top 10

Funds holding in top 10: 18 [Q3] → 28 (+10) [Q4]

15% more capital invested

Capital invested by funds: $85.7B [Q3] → $98.2B (+$12.5B) [Q4]

9% more funds holding

Funds holding: 1,691 [Q3] → 1,838 (+147) [Q4]

2.97% more ownership

Funds ownership: 82.21% [Q3] → 85.17% (+2.97%) [Q4]

10% less call options, than puts

Call options by funds: $864M | Put options by funds: $959M

11% less repeat investments, than reductions

Existing positions increased: 634 | Existing positions reduced: 709

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $90 16% downside
• Avg. target: $119 12% upside
• High target: $140 31% upside

11 analyst ratings

• positive: 9 82%
• neutral: 2 18%
• negative: 0 0%

Oppenheimer Hartaj Singh 26% 1-year accuracy 5 / 19 met price target	17% upside $125	Outperform Maintained	25 Apr 2025
Morgan Stanley Matthew Harrison 43% 1-year accuracy 10 / 23 met price target	27% upside $135	Overweight Maintained	25 Apr 2025
Cantor Fitzgerald Carter Gould 39% 1-year accuracy 12 / 31 met price target	17% upside $125	Overweight Assumed	22 Apr 2025
JP Morgan Chris Schott 41% 1-year accuracy 7 / 17 met price target	22% upside $130	Overweight Maintained	27 Mar 2025
B of A Securities Tim Anderson 47% 1-year accuracy 7 / 15 met price target	18% upside $126	Buy Maintained	5 Mar 2025